Off Patent
July 2026

Omegaven

fish oil triglycerides

Fresenius Kabi USA LLC

Emulsion (intravenous) · NDA 210589

Last listed protection ended
July 30, 2026

The FDA listed 2 patents and 1 exclusivity for Omegaven, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 9,629,821
    Claims the drug product and a use (U-2367)
  2. Ended
    Orphan drug exclusivity
    FDA code ODE-202
  3. Ended
    Patent 9,566,260
    Claims the drug product and a use (U-2366)